Ocular Therapeutix, Inc. (OCUL)
| Market Cap | 807.95M |
| Revenue (ttm) | 32.29M |
| Net Income (ttm) | -102.92M |
| Shares Out | 76.32M |
| EPS (ttm) | -1.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,113,049 |
| Open | 10.36 |
| Previous Close | 10.32 |
| Day's Range | 10.12 - 10.59 |
| 52-Week Range | 7.50 - 24.30 |
| Beta | 2.12 |
| Analysts | Buy |
| Price Target | 24.43 (+131.6%) |
| Est. Earnings Date | Nov 4, 2021 |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an ax...
Financial Performance
In 2020, OCUL's revenue was $17.40 million, an increase of 311.71% compared to the previous year's $4.23 million. Losses were -$155.64 million, 80.2% more than in 2019.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is 24.43, which is an increase of 131.56% from the latest price.
News
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapie...
This Exciting Biopharma Could Earn You 55% in 12 Months
When patients see more clearly, so too should investors.
4 Reasons I Just Bought Ocular Therapeutix Stock
This company's drug delivery technology just isn't getting the appreciation it deserves right now.
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -25.00% and 0.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulat...
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment o...
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...
After Plunging 19.8% in 4 Weeks, Here's Why the Trend Might Reverse for Ocular Therapeutix (OCUL)
The heavy selling pressure might have exhausted for Ocular Therapeutix (OCUL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street an...
Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) ...
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
3 Top Life Science Stocks to Buy on Sale Right Now
Shares of these overlooked gems could make investors very rich once the rest of the market notices their value.
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dr...
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Re...
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Please replace the release dated April 29, 2021, with the following corrected version due to multiple revisions. The updated release: OCULAR THERAPEUTIX...
Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Opht...
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...
Ocular Therapeutix™ To Report First Quarter 2021 Financial Results
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...